Skip to main content

Simultaneous determination of serum galectin-3 and -4 levels detects metastases in colorectal cancer patients

Cellular Oncology volume 36, pages 9–13 (2013)Cite this article

Abstract

Background

Development of effective ways to detect metastases is highly desirable for improving the therapeutic strategies and survival of cancer patients. Serum levels of galectin-3 and -4, two members of the galactoside-binding galectin family, have recently been reported to be markedly increased up to 31-fold in the bloodstream of colorectal cancer patients and in particular those with metastases.

Results

We found that simultaneous determination of serum galectin-3 and -4 levels in a single assay provides a high specificity and sensitivity in distinguishing colorectal cancer patients without metastases from those with liver metastases. This result was partly attributed by a reciprocal relationship of serum galectin-3 and -4 levels in patients with metastases. Higher serum galectin-3/-4 levels at the time of primary tumour removal in patients who did not exhibit clinically detectable metastases were associated with a trend of a poorer patients’ survival in the next 10 years.

Conclusion

Simultaneous determination of serum galectin-3 and -4 levels can potentially be used alone or in combination with other assessments to detect colorectal cancer metastases.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

USD 39.95

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Fig. 1
Fig. 2
Fig. 3

References

  1. P.D. Sasieni, J. Shelton, N. Ormiston-Smith et al., What is the lifetime risk of developing cancer?: the effect of adjusting for multiple primaries. Br. J. Cancer 105(3), 460–465 (2011)

    Article  PubMed  CAS  Google Scholar 

  2. G. Christofori, New signals from the invasive front. Nature 441(7092), 444–450 (2006)

    Article  PubMed  CAS  Google Scholar 

  3. H. Barrow, X. Guo, H.H. Wandall et al., Serum galectin-2, -4, and -8 are greatly increased in colon and breast cancer patients and promote cancer cell adhesion to blood vascular endothelium. Clin. Cancer Res. 17(22), 7035–7046 (2011)

    Article  PubMed  CAS  Google Scholar 

  4. S. Saussez, F. Lorfevre, T. Lequeux et al., The determination of the levels of circulating galectin-1 and -3 in HNSCC patients could be used to monitor tumor progression and/or responses to therapy. Oral Oncol. 44(1), 86–93 (2008)

    Article  PubMed  CAS  Google Scholar 

  5. S. Saussez, D. Glinoer, G. Chantrain et al., Serum galectin-1 and galectin-3 levels in benign and malignant nodular thyroid disease. Thyroid 18(7), 705–712 (2008)

    Article  PubMed  CAS  Google Scholar 

  6. M. Sakaki, N. Oka, R. Nakanishi et al., Serum level of galectin-3 in human bladder cancer. J. Med. Investig. 55(1–2), 127–132 (2008)

    Article  Google Scholar 

  7. I. Iurisci, N. Tinari, C. Natoli et al., Concentrations of galectin-3 in the sera of normal controls and cancer patients. Clin. Cancer Res. 6(4), 1389–1393 (2000)

    PubMed  CAS  Google Scholar 

  8. S. Senapati, P. Chaturvedi, W.G. Chaney et al., Novel interaction of MUC4 and galectin: potential pathobiological implications for metastasis in lethal pancreatic cancer. Clin. Cancer Res. 17(2), 267–274 (2011)

    Article  PubMed  CAS  Google Scholar 

  9. P. Vereecken, A. Awada, S. Suciu et al., Evaluation of the prognostic significance of serum galectin-3 in American Joint Committee on cancer stage III and stage IV melanoma patients. Melanoma Res. 19(5), 316–320 (2009)

    Article  PubMed  CAS  Google Scholar 

  10. L.G. Yu, Circulating galectin-3 in the bloodstream: an emerging promoter of cancer metastasis. World J. Gastrointest. Oncol. 2(4), 177–180 (2010)

    Article  PubMed  Google Scholar 

  11. Q. Zhao, X. Guo, G.B. Nash et al., Circulating galectin-3 promotes metastasis by modifying MUC1 localization on cancer cell surface. Cancer Res. 69(17), 6799–6806 (2009)

    Article  PubMed  CAS  Google Scholar 

  12. A.U. Newlaczyl, L.G. Yu, Galectin-3—a jack-of-all-trades in cancer. Cancer Lett. 313(2), 123–128 (2011)

    Article  PubMed  CAS  Google Scholar 

  13. L.G. Yu, N. Andrews, Q. Zhao et al., Galectin-3 interaction with Thomsen-Friedenreich disaccharide on cancer-associated MUC1 causes increased cancer cell endothelial adhesion. J. Biol. Chem. 282(1), 773–781 (2007)

    Article  PubMed  CAS  Google Scholar 

  14. Q. Zhao, M. Barclay, J. Hilkens et al., Interaction between circulating galectin-3 and cancer-associated MUC1 enhances tumour cell homotypic aggregation and prevents anoikis. Mol. Cancer 9, 154 (2010)

    Article  PubMed  Google Scholar 

  15. M. Watanabe, I. Takemasa, N. Kaneko et al., Clinical significance of circulating galectins as colorectal cancer markers. Oncol. Rep. 25(5), 1217–1226 (2011)

    PubMed  Google Scholar 

  16. H. Barrow, J.M. Rhodes, L.-G. Yu, The role of galectins in colorectal cancer progression. Int. J. Cancer 129, 1–8 (2011)

    Article  PubMed  CAS  Google Scholar 

  17. S.E. Baldus, F.G. Hanisch, G.M. Kotlarek et al., Coexpression of MUC1 mucin peptide core and the Thomsen-Friedenreich antigen in colorectal neoplasms. Cancer 82(6), 1019–1027 (1998)

    Article  PubMed  CAS  Google Scholar 

  18. R. Singh, B.J. Campbell, L.G. Yu et al., Cell surface-expressed Thomsen-Friedenreich antigen in colon cancer is predominantly carried on high molecular weight splice variants of CD44. Glycobiology 11(7), 587–592 (2001)

    Article  PubMed  CAS  Google Scholar 

  19. D.N. Cooper, S.H. Barondes, God must love galectins; he made so many of them. Glycobiology 9(10), 979–984 (1999)

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgment

This study was supported by a North West Cancer Research Fund grant CR777 (to LGY).

Conflict of interest

The authors declare no conflict of interest.

Author information

Authors and Affiliations

  1. Department of Gastroenterology, Institute of Translational Medicine, University of Liverpool, Liverpool, L69 3GE, UK

    Hannah Barrow, Jonathan M. Rhodes & Lu-Gang Yu

Authors
  1. Hannah Barrow
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jonathan M. Rhodes
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Lu-Gang Yu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Lu-Gang Yu.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Barrow, H., Rhodes, J.M. & Yu, LG. Simultaneous determination of serum galectin-3 and -4 levels detects metastases in colorectal cancer patients. Cell Oncol. 36, 9–13 (2013). https://doi.org/10.1007/s13402-012-0109-1

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13402-012-0109-1

Keywords

  • Galectin-3
  • Galectin-4
  • Metastasis
  • Colorectal cancer